Key result
High plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with cardiovascular mortality in end-stage renal disease and predict renal disease progression and death.
Why the study?
Is high plasma asymmetric dimethylarginine (ADMA) associated with increased cardiovascular and renal risk?
Is high plasma asymmetric dimethylarginine (ADMA) associated with increased cardiovascular and renal risk?
Answers are grounded in this paper and cite their sources.
ADMA is a significant biomarker linking atherosclerosis and renal insufficiency, predicting adverse cardiovascular and renal outcomes.
The endogenous inhibitor of the nitric oxide synthase, asymmetric dimethylarginine (ADMA), by reducing nitric oxide (NO) availability, may trigger pro-atherogenic effects. A high plasma concentration of this substance has been associated to intima-media thickening, left ventricular hypertrophy and all-cause and cardiovascular mortality in patients with end-stage renal disease, and to coronary events in males in the general population. Recent studies show that ADMA predicts renal disease progression and death in patients with moderate to severe renal insufficiency. ADMA may be at the crossroad of the atherosclerosis process and may represent an important factor in the high risk associated with renal insufficiency.
No takes yet. Share an insight, caveat, or question.
Carmine Zoccali (2006) conducted a review in Renal insufficiency and cardiovascular risk. Asymmetric dimethylarginine (ADMA) was evaluated. High plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with cardiovascular mortality in end-stage renal disease and predict renal disease progression and death.
Synapse has enriched 10 related papers. Consider them for comparative context: